Fiche société
Kariya Pharmaceuticals
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications1liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| KP405This study will explore the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of KP405 as a potential new treatment for Parkinson's disease. | Parkinson | Phase 1 | À vérifier | United Kingdom | À vérifier |
| KP405This study will explore the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of KP405 as a potential new treatment for Parkinson's disease. | Parkinson | Phase 1 | À vérifier | United Kingdom | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| KP405 | Parkinson | Phase 1 | NCT06189170 | Phase I Study to Evaluate KP405 in Healthy and Parkinson's Disease Patients | COMPLETED |
Publications
1| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| KP405 | A Dual GLP-1/GIP Receptor Agonist Is More Effective than Liraglutide in the A53T Mouse Model of Parkinson's Disease. | Parkinson's disease |